Sierra Oncology, Inc. (NASDAQ: SRRA) is focussed on creating novel targeted therapies that address large unmet needs in rare forms of cancer. The Company’s lead product candidate is momelotinib, a selective and orally bioavailable JAK1, JAK2 and ACVR1/ALK2 inhibitor being developed for the treatment of...
Magenta Therapeutics Inc (NASDAQ: MGTA), a Company pioneering research in stem cell transplant to reset the immune system in order to combat autoimmune, blood cancers and genetic diseases, provided a development update for MGTA-145, a CXCR2 agonist that is intended as a first-line therapy for...
According to an estimate by the Centers for Disease Control and Prevention (CDC), SCD affects over 100,000 Americans and is a major public health concern as it resulted in 75,000 hospitalizations between 1989 through 1993, and cost over $475 million. The Medical expenditure of children with...
G1 Therapeutics (NASDAQ: GTHX) shares soared by almost 25% on the basis of news that it had a productive phase 2 meeting with the FDA for the company’s lead candidate Trilaciclib, a first-in-class myelopreservation agent that protects the bone marrow from damage by chemotherapy. The...
